Clinical Trial Update: Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations [Phase 2]

View source ↗

Summary

Clinical trial comparing the EGFR inhibitor erlotinib against vinorelbine/cisplatin as adjuvant therapy for stage IIIA non-small cell lung cancer with EGFR muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Navelbine (vinorelbine)
• Tarceva (erlotinib)

Snippet

Sponsor: Chinese Lung Cancer Surgical Group | Conditions: Non-small Cell Lung Cancer Stage IIIA | Phase 2 | Status: UNKNOWN